Aldeyra Therapeutics announced that the U.S. Food and Drug Administration issued a Complete Response Letter on March 17 2026 for its New Drug Application for reproxalap, the company’s only near‑term product candidate for dry eye disease. The letter cites a lack of substantial evidence of efficacy and inconsistencies in the clinical data package, effectively rejecting the application and preventing the drug from moving toward approval or commercialization.
The rejection eliminates the possibility of a $100 million upfront payment and up to $300 million in milestone payments under the existing AbbVie option agreement. The option requires FDA approval to trigger the upfront and milestone payments, so the CRL removes a key source of potential upside for Aldeyra and signals a significant setback for the company’s revenue prospects.
Aldeyra’s financial position is already constrained. The company reported a net loss of $33.8 million for fiscal 2025 and an earnings‑per‑share of –$0.11 in Q4 2025, beating analyst estimates of –$0.12. As of December 31 2025, Aldeyra held $70 million in cash, cash equivalents, and marketable securities, which management expects to fund operations into 2028 after aggressive cost cuts. The CRL now forces the company to reassess its cash runway and explore alternative funding or partnership options.
The CRL is not the first FDA rejection for reproxalap. Aldeyra received similar letters in November 2023 and April 2025, both citing efficacy concerns and data inconsistencies. CEO Todd C. Brady said, “To the thousands of American and Canadian patients who participated in our clinical trials and to the tens of thousands of patients with dry eye disease worldwide, I want to assure you that we will work with urgency to support the FDA in enabling market access to what is, to our knowledge, the only drug with clinical activity within minutes of administration in patients with dry eye disease.” The repeated rejections underscore persistent regulatory challenges.
With the lead candidate’s approval path closed, Aldeyra faces a critical juncture. Management has announced plans to request a Type A meeting with the FDA to understand the next steps, while also evaluating alternative partners and other strategic options. The company’s cash runway, now extended to 2028, provides a buffer, but the loss of the AbbVie deal and the absence of a near‑term revenue generator heighten the urgency of these decisions.
The CRL represents a major setback for Aldeyra, eliminating a key revenue source, exposing persistent efficacy concerns, and forcing the company to confront a strategic crossroads as it seeks to secure its financial future and explore new pathways for its pipeline.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.